Abstracts tagged "human leukocyte antigens (HLA) and spondylarthropathy"

Abstract Number: 1580 • 2017 ACR/ARHP Annual Meeting
HLA-B27/ Human β2-Microglobulin (β2m) Transgenic Drosophila Expresses Specific Cross-Vein Less (CVL) and Small-Eye Phenotypes Resulting from Disruption of the BMP/TGFβ Signaling Pathway
Benjamin Grandon¹, Nadège Jah², Aurore Rincheval-Arnold³, Isabelle Guénal³, Sébastien Gaumer³, Claudine Andre², Maxime Breban⁴ and Gilles Chiocchia⁵, ¹Inserm UMR 1173 and LGBC, 78180 Saint Quentin en Yvelines, France, ²Infection and inflammation, INSERM UMR1173, Montigny-le-Bretonneux, France, ³Laboratory of Genetic and Cellular Biology, Faculty of Health Sciences Simone Veil, Montigny-le-Bretonneux,, 78180 SAINT QUENTIN EN YVELINES, France, ⁴Rheumatology, Ambroise Paré Hospital (AP-HP), Versailles Saint Quentin en Yvelines University, INSERM UMR1173, Boulogne-Billancourt, France, ⁵Service d'Immunologie, Ambroise Paré Hospital, University of Versailles Saint-Quentin-en-Yvelines, Boulogne, France, Boulogne-Billancourt, France
Background/Purpose: The association between HLA-B27 and spondyloarthritis (SpA) remains unexplained more than 40 years after its discovery. To further explore the pathogenic role of HLA-B27,…
Abstract Number: 594 • 2012 ACR/ARHP Annual Meeting
Evidence of Human Leucozyte Antigen-B27 in Healthy Individuals and Patients with Uveitis Is a Risk Factor for Alterations in Bone Metabolism
Sarah Schmidt¹, Stephanie Finzel¹, Jürgen Rech², Matthias Englbrecht¹, Silke Winkler¹, Isabel Schmidt¹, Roula Said-Nahal³, Maxime A. Breban³ and Georg A. Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medizinische Klinik 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France
Background/Purpose: To test whether positivity for HLA-B27 per se is associated with changes of biomarkers of the Wnt pathway. HLA-B27 is strongly associated with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].